Compare Avantis US Small Cap Value ETF (AVUV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Sana Biotechnology Inc — how do they compare? Avantis US Small Cap Value ETF trades at $124.71, while Sana Biotechnology Inc trades at $3.51 (market cap $994.89M). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AVUV | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $124.94 | $5.92 |
52-Week Low | $90.37 | $2.68 |
Market Cap | — | $994.89M |
Enterprise Value | — | $969.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $123.97, up 0.02% on the day, with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. small-cap value stocks, which have outperformed growth peers in 2026, driven by shifting rate expectations. Recent news highlights its role in diversifying tech-heavy portfolios and capturing the small-cap value premium.
Outlook remains positive as small-cap value gains favor amid economic shifts, though risks include higher volatility and sensitivity to interest rates. The fund offers growth potential but requires tolerance for the inherent risks of smaller companies.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
